Management of Advanced Stage Hodgkin Lymphoma

in Journal of the National Comprehensive Cancer Network

Although advanced Hodgkin lymphoma is highly curable, balancing the high cure rate with long-term toxicity is challenging. ABVD (doxorubicin [Adriamycin], bleomycin, vinblastine, dacarbazine) is the standard chemotherapy regimen, producing a high cure rate with acceptable toxicity. Stanford V and BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) are new regimens with encouraging results and are undergoing randomized clinical trials. The International Prognostic Score provides a clinical tool that may help identify patients with high-risk disease who may require a more aggressive regimen. Consolidative radiation's role in managing advanced Hodgkin lymphoma is still controversial, but it is most accepted for bulky or residual disease or after brief chemotherapy. The development and integration of newer imaging tools, such as fluorodeoxyglucose–positron emission tomography imaging, may allow a more precise evaluation of disease and help define which patients might benefit from consolidative treatment.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Article Details

Correspondence: Ranjana Advani, MD, Stanford Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305. E-mail:


  • 1.

    LongoDYoungRWesleyM. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol1986;4:12951306.

  • 2.

    DeVitaVTJrSimonRMHubbardSM. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med1980;92:587595.

  • 3.

    VoseJBiermanPAndersonJ. CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity. J Clin Oncol1991;9:14211425.

  • 4.

    HardingMJMcNultyLJPaulJ. Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease. Eur J Cancer1991;27:10021006.

  • 5.

    HancockBWVaughan HudsonGVaughan HudsonB. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease—long term results. Br J Cancer1991;63:579582.

  • 6.

    BonadonnaGZucaliRMonfardiniS. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer1975;36:252259.

  • 7.

    CanellosGPAndersonJRPropertKJ. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med1992;327:14781484.

  • 8.

    CanellosGPNiedzwieckiD. Long-term follow-up of Hodgkin's disease trial. N Engl J Med2002;346:14171418.

  • 9.

    VivianiSBonadonnaGSantoroA. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol1996;14:14211430.

  • 10.

    GlickJHYoungMLHarringtonD. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol1998;16:1926.

  • 11.

    DugganDBPetroniGRJohnsonJL. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol2003;21:607614.

  • 12.

    VivianiSSantoroARagniG. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol1985;21:601605.

  • 13.

    HasencleverDDiehlV. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med1998;339:15061514.

  • 14.

    HorningSJHoppeRTBreslinS. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol2002;20:630637.

  • 15.

    HorningSJHoppeRAdvaniR. Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: mature data in early and advanced stage patients [abstract]. Blood2004;104Abstract 308.

  • 16.

    YahalomJEdwards-BennetSJacobsJ. Stanford V and radiotherapy for advanced and locally extensive Hodgkin's disease (HD): the Memorial Sloan-Kettering Cancer Center (MSKCC) experience [abstract]. Blood2003Abstract 1459.

  • 17.

    HorningSJWilliamsJBartlettNL. Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group Pilot Study E1492. J Clin Oncol2000;18:972980.

  • 18.

    AversaSMSalvagnoLSoraruM. Stanford V regimen plus consolidative radiotherapy is an effective therapeutic program for bulky or advanced-stage Hodgkin's disease. Acta Haematol2004;112:141147.

  • 19.

    JohnsonPHoskinPHorwichA. Stanford V (SV) regimen versus ABVD for the treatment of advanced Hodgkin lymphoma (HL): results of a UK NCRI/LTO randomised phase II trial [abstract]. Blood2004;104Abstract 311.

  • 20.

    GobbiPGLevisAChisesiT. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol2005;23:91989207.

  • 21.

    HasencleverDLoefflerMDiehlV. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol1996;7[suppl 4]:9598.

  • 22.

    DiehlVFranklinJPfreundschuhM. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med2003;348:23862395.

  • 23.

    ConnorsJM: State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol2005;23:64006408.

  • 24.

    DiehlVBrillantCFranklinJ. BEACOPP chemotherapy for advanced Hodgkin's disease: results of further analyses of the HD9- and HD12-trials of the German Hodgkin Study Group (GHSG) [abstract]. Blood2004;104Abstract 307.

  • 25.

    SieberMBredenfeldHJostingA. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol2003;21:17341739.

  • 26.

    MarkovaJZidkaMKozakT. Osteonecrosis as a complication of treating Hodgkin's lymphoma after BEACOPP chemotherapy. Ann Oncol2005;16(Suppl 5). Abstract 269.

  • 27.

    FedericoMBelleiMBriceP. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol2003;21:23202325.

  • 28.

    ProctorSJMackieMDawsonA. A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III). Eur J Cancer2002;38:795806.

  • 29.

    YoungRCCanellosGPChabnerBA. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer1978;42:10011007.

  • 30.

    LoefflerMBrosteanuOHasencleverD. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol1998;16:818829.

  • 31.

    FermeCSebbanCHennequinC. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood2000;95:22462252.

  • 32.

    HancockSLHoppeRTHorningSJ. Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med1988;109:183189.

  • 33.

    AlemanBMRaemaekersJMTirelliU. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med2003; 348:23962406.

  • 34.

    LaskarSGuptaTVimalS. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?J Clin Oncol2004;22:6268.

  • 35.

    FriedbergJWFischmanANeubergD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma2004;45:8592.

  • 36.

    WirthASeymourJFHicksRJ. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med2002;112:262268.

  • 37.

    NaumannRBeuthien-BaumannBReissA. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma. Br J Cancer2004;90:620625.

  • 38.

    SpaepenKStroobantsSDupontP. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?Br J Haematol2001;115:272278.

  • 39.

    JerusalemGBeguinYFassotteMF. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol2003;14:123130.

  • 40.

    WeihrauchMRReDScheidhauerK. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood2001;98:29302934.

Article Information


Google Scholar

Related Articles


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 15 15 3
PDF Downloads 1 1 0
EPUB Downloads 0 0 0